KBC Group’s Editas Medicine EDIT Stock Holding History

KBC Group’s Portfolio EDIT Stock Details EDIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-2,250	Closed	-$92K	–	1299
2021 Q3	$92K	Sell	2,250 -5,250	-70%	-$288K	﹤0.01%	1180
2021 Q2	$424K	Hold	7,500	–	–	﹤0.01%	1081
2021 Q1	$316K	Buy	7,500 +2,000	+36%	+$114K	﹤0.01%	1125
2020 Q4	$2.12M	Sell	5,500 -2,900	-35%	-$119K	﹤0.01%	1054
2020 Q3	$236K	Hold	8,400	–	–	﹤0.01%	1098
2020 Q2	$248K	Buy	8,400 +1,700	+25%	+$44.4K	﹤0.01%	1122
2020 Q1	$133K	Hold	6,700	–	–	﹤0.01%	1099
2019 Q4	$198K	Buy	6,700 +5,680	+557%	+$142K	﹤0.01%	1285
2019 Q3	$23K	Sell	1,020 -2,980	-75%	-$73.8K	﹤0.01%	1436
2019 Q2	$99K	Hold	4,000	–	–	﹤0.01%	1304
2019 Q1	$98K	Buy	4,000 +2,400	+150%	+$54.3K	﹤0.01%	1278
2018 Q4	$36K	Hold	1,600	–	–	﹤0.01%	1237
2018 Q3	$51K	Hold	1,600	–	–	﹤0.01%	1331
2018 Q2	$57K	Hold	1,600	–	–	﹤0.01%	1216
2018 Q1	$53K	Hold	1,600	–	–	﹤0.01%	1218
2017 Q4	$49K	Buy	+1,600	New	+$40.3K	﹤0.01%	1205

Other funds holding EDIT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

KBC Group's EDIT Position: Q4 2021 in Review

KBC Group sold out of Editas Medicine (EDIT) in Q4 2021, closing a stake of 2,250 shares — an estimated $92K sold.

KBC Group first reported a position in EDIT in Q4 2017 and held it in 16 quarters. The position peaked at $2.12M in Q4 2020. 305 funds tracked by Wall St. Rank hold EDIT as of Q4 2021.

KBC Group reported no remaining Editas Medicine position as of Q4 2021 after selling out during the quarter.
KBC Group sold 2,250 Editas Medicine shares in Q4 2021, an estimated $92K.
KBC Group first reported a position in Editas Medicine in Q4 2017 and held it in 16 quarters.
KBC Group's Editas Medicine position peaked at $2.12M in Q4 2020.
305 funds tracked by Wall St. Rank held Editas Medicine as of Q4 2021.

Based on KBC Group's 13F filing for Q4 2021, filed 3 Feb 2022.